Italy Cardiovascular Drug Industry Outlook 2022 - 2026

See how Italy Cardiovascular Drug performed compared to key markets such as Germany and Canada.

Key Market Indicators

Sales of beta-blocking medicines in Italy are set to reach €420 million (rounded to €400 million) by 2026. This would mark a growth of 0.8% year on year, according to a new report. Since 2016, the Italian market has grown by 3.8% year on year. In 2021, Germany overtook Italy, with sales of €457.93 million (rounded to €460 million). Italy, Canada and Australia were ranked second, third and fourth respectively.

Italy Cardiovascular Drug Market Data and Forecasts

Italy Cardiovascular Drug : how will it grow in the coming years?

Forecast: Cardiovascular System Medicine Sales in Italy
Forecast: Cardiac Glycosides Sales in Italy
Forecast: Cardiac Glycosides Sales in Italy
Forecast: Cardiac Glycosides Sales in Italy
Forecast: Cardiovascular System Medicine Sales in Italy
Forecast: Antiarrhythmic Medicine Sales in Italy
Forecast: Calcium Channel Blocking Medicine Sales in Italy
Forecast: Cardiovascular System Medicine Sales in Italy
Forecast: Beta Blocking Medicine Sales in Italy
Forecast: Diuretic Medicine Sales in Italy
View More

Other Top Countries about Cardiovascular Drug